home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

World Pharma Congress 2013

  March 01, 2013  
Loews Philadelphia Hotel, 1200 Market Street, Philadelphia, PA 19107
June 4-6, 2013

After a dozen years covering various topics for the pharmaceutical industry, the World Pharma Congress has found its niche in effectively covering the latest preclinical strategies and technologies for driving better predictions. Building on its experience covering drug targets, high-throughput screening, lead optimization, ADME and drug safety, the event is now primed to move further downstream into early formulations and drug delivery.

2013 Conference Programs:
  • 2nd Annual Predictive Preclinical Models in Oncology:  Challenging Cancer Heterogeneity with Reproducible and Predictive Preclinical Studies
  • 6th Annual Targeting Pain with Novel Therapeutics:  Translating Success from Preclinical Assays to the Clinic
  • Inaugural Accelerating Development of Difficult-to-Deliver Drugs:  Driving Innovation Through Effective Tools and Novel Drug Delivery Strategies
  • 6th Annual Integrated Drug Safety Risk Assessments:  Predicting Drug-Induced Organ Toxicities Using Functional Assays, Models and Marker
  • 4th Annual Molecular Imaging in Drug Discovery and Development:  Integrating Molecular Imaging Technologies to Improve Preclinical Findings
Short Courses:
  1. Addressing Safety Concerns for Biologics and Biosimilars
  2. Utilization of Cardiac Contractility Assays for Preclinical Safety Testing
  3. Animal Models of Pain: Progress and Challenges
  4. Design and Interpretation of Stability Studies for Difficult Drugs
  5. Use of Stem Cells for Safety Screening
  6. Introduction to Drug Metabolism and Its Role in Drug Toxicity
  7. Epigenetic Mechanisms of Pain
  8. Development of Nanotechnology Application into Innovative Therapies
  9. Roadmap for Outsourcing of Preclinical Imaging
  10. Advances in Imaging Quantitation
  11. Genetically Engineered Mouse Models versus Patient-Derived Xenograft Models: Comparing Strengths and Limitations
Organized by: Cambridge Healthtech Institute
Invited Speakers:
Speakers Include:
Kevin Webster, Ph.D., Vice President, Oncology Research, AstraZeneca

Eric Holland, M.D., Ph.D., Director, Brain Tumor Center; Vice Chair, Translational Research, Department of Surgery, Emily Tow Jackson Chair in Oncology, Memorial Sloan Kettering Cancer Center.

Terry A. Van Dyke, Ph.D., Head, Mouse Cancer Genetics Program; Program Director, Cancer Pathways and Mechanisms, National Cancer Institute

Norman M. Greenberg, Ph.D., Vice President, Research and Development, MedImmune

David Heimbrook, Ph.D., CEO, SAIC-Frederick National Laboratory for Cancer Research

David Sidransky, MD, Chairman & Co-Founder, Champions Oncology, Inc.

Karim Dabbagh, Ph.D., Executive Director and Head, External R&D and Innovation Research Units, Pfizer Worldwide R&D

Glen N. Gaulton, Ph.D., Professor, Pathology and Laboratory Medicine; Executive Vice Dean and CSO, Perelman School of Medicine, University of Pennsylvania

Peter Pitts, President and Co-Founder, Center for Medicine in the Public Interest

Dr. Andrew L. Kung, M.D., Ph.D., Director, Pediatric Hematology, Oncology and Stem Cell Transplantation, New York-Presbyterian Morgan Stanley Children’s Hospital/Columbia University Medical Center

Jeffrey E. Green, M.D. Head, Transgenic Oncogenesis and Genomics Section, Center for Cancer Research, National Cancer Institute

Glenn Merlino, Ph.D., Chief, Molecular Genetics Section, Laboratory of Molecular Biology, Division of Basic Science, National Cancer Institute

Henry Smilowitz, Ph.D., Associate Professor, Cell Biology, University of Connecticut Health Center

Celina D’Cruz, Ph.D., Principal Scientist I, Oncology Innovative Medicines, R&D, AstraZeneca

Dylan Daniel, Ph.D., Investigator III, Oncology Pharmacology, Novartis Institutes for Biomedical Research

Neal Goodwin, Ph.D., Director, Research and Development, In Vivo Pharmacology Services, The Jackson Laboratory

Martin Carroll, M.D., Associate Professor, Division of Hematology and Oncology, University of Pennsylvania School of Medicine 

Hui Gao, Ph.D., Investigator III, Novartis Institutes for Biomedical Research

Tan A. Ince, M.D., Ph.D., Director, Tumor Stem Cell Division, Interdisciplinary Stem Cell Institute and Associate Professor of Pathology, Braman Family Breast Cancer Institute, Miller School of Medicine, University of Miami

Prem K. Premsrirut, Ph.D., CEO, Mirimus, Inc.

Andrew Rhim, M.D., Instructor of Medicine, Gastroenterology/Medicine, University of Pennsylvania

Peter King, Ph.D., Senior Scientist, Molecular Imaging (Oncology), Janssen, Pharmaceutical Companies of Johnson and Johnson

Charles Glaus, Ph.D., Scientist, Research Imaging Sciences, Amgen

Werner Scheuer, Research Leader, Pharma Research and Early Development, Discovery Oncology; Roche Diagnostics GmbH

Willem Mulder, Ph.D., Associate Professor of Radiology, Director, Nanomedicine Program, Translational and Molecular Imaging Institute, Mount Sinai School of Medicine

Theresa Zhang, Ph.D., Associate Director, Merck Research Laboratories

Darrin Stuart, Senior Research Investigator II, Novartis Institutes for Biomedical Research

Erica Jackson, Ph.D., Scientist, Research Group Leader, Genentech

Chandan Kumar-Sinha, Ph.D., Research Assistant Professor, Pathology, University of Michigan 
Deadline for Abstracts: April 19, 2013


E-mail: kwaterman@healthtech.com
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.